

## UNITED STATES PATENT AND TRADEMARK OFFICE



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

. APPLICATION NO.	F	ILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/781,693	09/781,693 02/12/2001		Tai-Jay Chang	11709-003001 / 6148 0674-5737U	
26161	7590	03/26/2003			
FISH & RI		SON PC	EXAMINER		
225 FRANKLIN ST BOSTON, MA 02110				PAK, MICHAEL D	
				ART UNIT	PAPER NUMBER
				1646	17
				DATE MAILED: 03/26/2003	15

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)					
Office Action Summers	09/781,693	CHANG, TAI-JAY					
Office Action Summary	Examiner	Art Unit					
·	Michael Pak	1646					
The MAILING DATE of this communication app Period for Reply	The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply						
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.  - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.  - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.  - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.  - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).  - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).  Status							
1) Responsive to communication(s) filed on	·						
	is action is non-final.						
3) Since this application is in condition for allowa	ance except for formal matters, p	rosecution as to the merits is					
closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213. <b>Disposition of Claims</b>							
4) Claim(s) 1-34 is/are pending in the application	l <b>.</b>						
4a) Of the above claim(s) is/are withdraw	wn from consideration.						
5) Claim(s) is/are allowed.							
6) Claim(s) is/are rejected.							
7) Claim(s) is/are objected to.							
8) Claim(s) 1-34 are subject to restriction and/or	election requirement.						
Application Papers							
9)☐ The specification is objected to by the Examine	r.						
10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.							
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).							
11) The proposed drawing correction filed on is: a) approved b) disapproved by the Examiner.							
If approved, corrected drawings are required in reply to this Office action.							
12)☐ The oath or declaration is objected to by the Examiner.							
Priority under 35 U.S.C. §§ 119 and 120							
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).							
a) ☐ All b) ☐ Some * c) ☐ None of:							
1. Certified copies of the priority documents have been received.							
2. Certified copies of the priority documents	s have been received in Applicati	on No					
3. Copies of the certified copies of the priority documents have been received in this National Stage							
application from the International Bureau (PCT Rule 17.2(a)).  * See the attached detailed Office action for a list of the certified copies not received.							
14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).							
<ul> <li>a) ☐ The translation of the foreign language provisional application has been received.</li> <li>15)☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.</li> </ul>							
Attachment(s)							
1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449) Paper No(s)	5) Notice of Informal I	y (PTO-413) Paper No(s) Patent Application (PTO-152)					
S. Patent and Trademark Office PTO-326 (Rev. 04-01) Office Ac	tion Summary	Part of Paner No. 13					

Art Unit: 1646

## **DETAILED ACTION**

## Election/Restrictions

- 1. Restriction to one of the following inventions is required under 35 U.S.C. 121:
  - I. Claims 1-7, drawn to a polypeptide, classified in class 530, subclass 350.
  - II. Claims 8-25, drawn to nucleic acids, vectors, host cells, and methods of producing protein recombinantly, classified in class 435, subclass 69.1.
  - III. Claim 26, drawn to method for screening for a compound that decreases, classified in class 435, subclass 7.2.
  - IV. Claims 27-28, drawn to antibody, classified in class 530, subclass 387.1.
  - V. Claim 29-30, drawn to method of determining cancer cells, classified in class 435, subclass 6.
  - VI. Claim 31-34, drawn to a method of treating cancer, classified in class 424, subclass 130.1.

The inventions are distinct, each from the other because of the following reasons:

The inventions are distinct, each from the other because of the following reasons:

The products of inventions I, II and IV, are distinct each from the other, because they are drawn to products having different structures and functions.

The methods of inventions III, V, and VI are distinct, each from the other, because they are drawn to processes having materially different process steps, which are practiced for materially different purposes.

The products of invention I, and the processes invention III are related as product and process of use. The inventions can be shown to be distinct if either or both of the

Art Unit: 1646

following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case the products of group I can be used for generating antibodies.

The products of invention I is not used by or produced by the methods of Group V and VI.

The products of invention II, and the processes invention V are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case the products of group II can be used for mutating a transgenic mouse.

The products of invention II are not used by or produced by the methods of Group III and VI.

The products of invention IV, and the processes invention VI are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case the products of group IV can be used for diagnostic detection.

The products of invention IV are not used by or produced by the methods of Group III and V.

Art Unit: 1646

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art because of their recognized divergent subject matter, separate search requirements, and different classification, restriction for examination purposes as indicated is proper.

A telephone call was made to Attorney Rocky Tsao on 13 March 2003 to request an oral election to the above restriction requirement, but did not result in an election being made.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

2. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Michael Pak, whose telephone number is (703) 305-7038. The examiner can normally be reached on Monday through Friday from 8:30 AM to 2:00 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Yvonne Eyler, can be reached on (703) 308-6564.

Official papers filed by fax should be directed to (703) 308-4242. Faxed draft or informal communications with the examiner should be directed to (703) 308-0294.

Art Unit: 1646

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Group receptionist whose telephone number is (703) 308-0196.

Hickorf D. PMC Michael Pak

**Primary Patent Examiner** 

Art Unit 1646

24 March 2003